Yabao Pharmaceutical Group   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (1978)
Status: No NME R&D (1978)

Organization Overview

First Clinical Trial
2015
NCT02599337
First Marketed Drug
2006
meloxicam (mobic)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Suzhou Yabao Pharmaceutical R&D Co., Ltd. | YABAO PHARM | Yabao Pharmaceutical Group | Yabao pharmaceutical Group Co.

Active Ingredients

Marketed Drugs (4)

celecoxib (celebrex) (2023)

galantamine (reminyl) (2009)

meloxicam (mobic) (2006)

sorafenib (nexavar) (2022)

Drugs in Phase 2 Trials (3)

globalagliatin (4 trials)

sy-005 (2 trials)

sy-009 (3 trials)

Drugs in Phase 1 Trials (6)

rifampin (1 trial)

sorafenib (nexavar) (1 trial)

sy-004 (1 trial)

sy-007 (1 trial)

sy-008 (2 trials)

ybsw015 (1 trial)

Drugs in Other Trials (1)

maltodextrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hyperglycemia (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 10